Study of LM11A-31-BHS in Mild-moderate AD Patients

NCT03069014 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Alzheimer's Disease

Interventions

DRUG: 400mg LM11A-31-BHS
DRUG: 800mg LM11A-31-BHS
DRUG: Placebos

Sponsor

PharmatrophiX Inc.

Collaborators

[object Object]